These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Noninvasive assessment of cardiomyopathy development with simultaneous measurement of topical 1H- and 31P-magnetic resonance spectroscopy. Toyo-oka T; Nagayama K; Suzuki J; Sugimoto T Circulation; 1992 Jul; 86(1):295-301. PubMed ID: 1319856 [TBL] [Abstract][Full Text] [Related]
27. Observation of intramyocellular lipids by 1H-magnetic resonance spectroscopy. Boesch C; Kreis R Ann N Y Acad Sci; 2000 May; 904():25-31. PubMed ID: 10865706 [TBL] [Abstract][Full Text] [Related]
28. Proton magnetic resonance spectroscopic imaging as a cancer biomarker for pediatric brain tumors (Review). Tzika AA Int J Oncol; 2008 Mar; 32(3):517-26. PubMed ID: 18292928 [TBL] [Abstract][Full Text] [Related]
29. Ex vivo 1H and 31P magnetic resonance spectroscopy as a means for tumor characterization in ovarian cancer patients. Abramov Y; Carmi S; Anteby SO; Ringel I Oncol Rep; 2013 Jan; 29(1):321-8. PubMed ID: 23042519 [TBL] [Abstract][Full Text] [Related]
31. Proton magnetic resonance spectroscopy (MRS) of metastatic brain tumors: variations of metabolic profile. Chernov MF; Hayashi M; Izawa M; Ono Y; Hori T Int J Clin Oncol; 2006 Oct; 11(5):375-84. PubMed ID: 17058135 [TBL] [Abstract][Full Text] [Related]
32. Association of 99mTc-MIBI brain SPECT and proton magnetic resonance spectroscopy (1H-MRS) to assess glioma recurrence after radiotherapy. Palumbo B; Lupattelli M; Pelliccioli GP; Chiarini P; Moschini TO; Palumbo I; Siepi D; Buoncristiani P; Nardi M; Giovenali P; Palumbo R Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):88-93. PubMed ID: 16557208 [TBL] [Abstract][Full Text] [Related]
33. Magnetic resonance spectroscopy in clinical oncology. Golder W Onkologie; 2004 Jun; 27(3):304-9. PubMed ID: 15249722 [TBL] [Abstract][Full Text] [Related]
34. Comparison of 1H-MRS-detected metabolic characteristics in single metastatic brain tumors of different origin. Chernov MF; Ono Y; Kubo O; Hori T Brain Tumor Pathol; 2006 Apr; 23(1):35-40. PubMed ID: 18095117 [TBL] [Abstract][Full Text] [Related]
35. Effects of hepatic impairment on the metabolism of fructose and 5-fluorouracil, as studied in fatty liver models using in vivo 31P-MRS and 19F-MRS. Otsuka H; Harada M; Koga K; Nishitani H Magn Reson Imaging; 1999 Feb; 17(2):283-90. PubMed ID: 10215484 [TBL] [Abstract][Full Text] [Related]
36. The use of proton MRS in the differential diagnosis of brain tumors and tumor-like processes. Gajewicz W; Papierz W; Szymczak W; Goraj B Med Sci Monit; 2003 Sep; 9(9):MT97-105. PubMed ID: 12960934 [TBL] [Abstract][Full Text] [Related]
37. [Application value of 3T 1H-magnetic resonance spectroscopy in diagnosing tumors of bone and soft tissue]. Qi ZH; Li CF; Ma XX; Li ZF; Zhang K; Yu DX Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Oct; 33(5):504-10. PubMed ID: 22338133 [TBL] [Abstract][Full Text] [Related]
38. Non-negative matrix factorisation methods for the spectral decomposition of MRS data from human brain tumours. Ortega-Martorell S; Lisboa PJ; Vellido A; Julià-Sapé M; Arús C BMC Bioinformatics; 2012 Mar; 13():38. PubMed ID: 22401579 [TBL] [Abstract][Full Text] [Related]
39. Comparison of 1.5T and 3T 1H MR spectroscopy for human brain tumors. Kim JH; Chang KH; Na DG; Song IC; Kim SJ; Kwon BJ; Han MH Korean J Radiol; 2006; 7(3):156-61. PubMed ID: 16969044 [TBL] [Abstract][Full Text] [Related]
40. Comparison of 31P MRS and 1H MRI at 1.5 and 2.0 T. Boska MD; Hubesch B; Meyerhoff DJ; Twieg DB; Karczmar GS; Matson GB; Weiner MW Magn Reson Med; 1990 Feb; 13(2):228-38. PubMed ID: 2314213 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]